It has been almost 20 years since the first conjugated pneumococcal vaccine (PCV) was introduced into childhood immunization schedules in the United States. Dramatic reductions in invasive pneumococcal disease (IPD) burden have been reported not only among children targeted for vaccination but also among unvaccinated children and adults in all settings following widespread use of the vaccine. These reductions are associated with reductions in nasopharyngeal colonization by vaccine serotypes and reduced transmission from vaccinated children.1 However, disease is not evenly distributed, and children with underlying clinical conditions are disproportionately represented among cases of IPD, especially among children older than 5 years.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Pelton SI, Lapidot R, Yildirim I. Invasive Pneumococcal Disease—Not Evenly Shared by All Children. JAMA Pediatr. Published online September 30, 2019. doi:10.1001/jamapediatrics.2019.3185
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: